Notice of Results

RNS Number : 2196A

Epistem Holdings plc

17 February 2014

 

Epistem Holdings Plc

("Epistem" or "the Company")

Interim Results Date

Epistem Holdings Plc (LSE: EHP), the biotechnology and personalised medicine company, will be announcing its unaudited interim results for the six months ended 31 December 2013 on Tuesday, 25 March 2014.

An analysts' meeting will be held at No 1 King Street, London EC2V 8AU at 9.30 am.

Epistem Plc
Matthew Walls	Chief Executive Officer	[phone]
John Rylands	Finance Director	[phone]
Peel Hunt LLP
James Steel		[phone]
Clare Terlouw		[phone]
Wallbrook PR
Mike Wort / Anna Dunphy		[phone]

Notes to Editors:

About Epistem

Epistem is a biotechnology and personalised medicine company, commercialising its expertise in epithelial stem cells, pharmacogenomics and diagnostics in the areas of oncology, gastrointestinal, dermatological and infectious disease.

Epistem develops biomarkers and molecular diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.

 

END

 

 

NORFMGMZLNFGDZG